August 25, 2015 by Chain Drug Review
Amneal Biosciences, Amneal Pharmaceuticals, Charles Lucarelli, Chirag Patel, generic drugs, specialty pharmaceuticals
Pharmacy, Supplier News
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has formed Amneal Biosciences, a new business unit. Amneal said Tuesday that the new subsidiary will focus exclusively on the commercialization of high-barrier-to-entry generic drugs and specialty pharmaceuticals — such as injectables, oncologics and biosimilars — health care providers worldwide. “Having a dedicated company focused on the unique needs and
July 22, 2015 by Chain Drug Review and Chain Drug Review
biopharmaceutical industry, biosimilars, Chester "Chip" Davis, Craig Wheeler, generic drugs, Generic Pharmaceutical Association, GPhA, Ralph Neas
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in
July 21, 2015 by Chain Drug Review and Chain Drug Review
B. Douglas Hoey, below-cost reimbursements, generic drugs, H.R. 244, independent community pharmacies, MAC Transparency Act, National Community Pharmacists Association, NCPA, PBM reimbursement, pharmacy benefit managers
Leading Headlines, Pharmacy, Retail News
ALEXANDRIA, Va. — The National Community Pharmacists Association said it has compiled evidence that underscores the need for federal sunshine legislation to provide more insight into below-cost reimbursements from pharmacy benefit managers that don’t keep pace with rising market costs for generic drugs. NCPA said Monday that it recently asked members for examples illustrating the
June 5, 2015 by Chain Drug Review
Cardinal Health, drug distribution business, generic drugs, George Barrett, Harvard Drug Group, pharmaceutical distributor
Business, Featured Articles, Leading Headlines, Pharmacy, Retail News
DUBLIN, Ohio — Cardinal Health Inc. plans to acquire pharmaceutical distributor The Harvard Drug Group (THDG) from private equity firm Court Square Capital Partners for $1.115 billion. Cardinal said Friday that it will use cash and new debt to finance the transaction, which is expected to close in the beginning of its 2016 fiscal year,
April 2, 2015 by Chain Drug Review and Chain Drug Review
Extra Value Drug List, generic drugs, Jill Turner-Mitchael, prescription savings program, Sam's Club
Leading Headlines, Pharmacy, Retail News
BENTONVILLE, Ark. — Sam’s Club is offering some generic drugs free under an expanded prescription savings program. The Walmart warehouse club chain said Thursday five generic medications are now available in specified quantities at no charge in 35 states for its Sam’s Club Plus and Business Plus members. They include donepezil (for Alzheimer’s disease), pioglitazone
March 23, 2015 by Chain Drug Review and Chain Drug Review
Apotex, Canadian Generic Pharmaceutical Association, Canadian prescription drug market, generic drugs, Jeff Watson, Larry MacGirr, Pharmascience
Pharmacy, Supplier News
TORONTO — Jeff Watson, president of global generics at Apotex, has been elected as chairman of the Canadian Generic Pharmaceutical Association (CGPA). CGPA also said Monday that Larry MacGirr, chief operating officer of Pharmascience, has been elected as the association’s vice chairman. “It is an honor to serve as chair of CGPA, particularly during this period
February 16, 2015 by Mark Tosh and Chain Drug Review
Doug Long, generic Copaxone, generic drug industry, generic drugs, generic Nexium, IMS Health, Red Oak Sourcing
Issue 02-16-2015, News, Pharmacy
NEW YORK — As the nation becomes more focused on affordable health care, generic drug companies are carving out a larger share of the U.S. market for prescription drugs. Perhaps the most significant sign of this continuing shift to generic drug utilization shows up in the market share data for actual prescriptions dispensed, brands compared
January 19, 2015 by John Schultz and Chain Drug Review
Affordable Prescription Drugs, biologics exclusivity, Centers for Medicare & Medicaid Services, drug costs, generic drug price spikes, generic drug use, generic drugs, Generic Pharmaceutical Association, GPhA, Medicare Part D, Medicare Payment Advisory Committee, MedPAC, Peter Welch, Ralph Neas, Sen. Bill Nelson, Sen. Susan Collins, Senate Special Committee on Aging, Steve Stivers
2015, Issue 01-19-2015, News, Pharmacy
WASHINGTON — Providing incentives to prescription drug plan sponsors that increase generic drug use is among recommendations that the Senate Special Committee on Aging unveiled last month in a bipartisan report that focuses on ways to increase the utilization of generics within the Medicare Part D program. The panel also heard about industry issues beyond